Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
NEW YORK, Feb. 13, 2018 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of investors who purchased Aradigm Corporation ("Aradigm") (NASDAQ:ARDM) securities between July 27, 2017 and January 8, 2018.
Click here to learn about the case: http://www.wongesq.com/pslra-sb/aradigm-corporation?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (i) the methodology underlying Aradigm's Linhaliq Phase III clinical trials was not well tailored to yield consistent efficacy findings or to provide data sufficient to account for discordant efficacy findings; (ii) the endpoint of the Phase III trials was unlikely to demonstrate a clinically meaningful benefit with respect to a patient population that would likely be taking the drug for a longer duration; (iii) accordingly, these studies were unlikely to support FDA approval of the Linhaliq NDA; and (iv) as a result, Aradigm's public statements were materially false and misleading at all relevant times.
On January 9, 2018, the FDA released its briefing document for the January 11, 2018 meeting of the Antimicrobial Drugs Advisory Committee to discuss the NDA for Linhaliq for the proposed indication of treatment of non-cystic fibrosis bronchiectasis. The FDA recommended Aradigm conduct “two independent trials” to provide evidence supporting the drug’s “overall demonstration of efficacy and safety.”
If you suffered a loss in Aradigm you have until March 12, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sb/aradigm-corporation?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
